Open Pharma position statement on open access

Pharmaceutical companies, which fund approximately half of all biomedical research,¹ are now leaders in the publication and disclosure of research.²,³ However, access to much company-funded research is restricted by journal paywalls.⁴ We, as Open Pharma, a group of pharmaceutical companies and other research funders, alongside healthcare professionals, regulators, patients, publishers and other stakeholders in healthcare, recognize the importance of publishing research with open access, where papers can be read without payment of a one-off access charge or subscription. Open access ensures that the highest quality, peer-reviewed evidence is available to anyone who needs it, anywhere in the world. Publishing with open access improves transparency, advances medical science and, we believe, ultimately improves patient care.

Our immediate priority

Our immediate priority is to secure authors publishing company-funded research the same right to publish open access as authors publishing research funded by other sources, so that all research can be made free to read from the date of publication. This would enable pharmaceutical companies to follow the lead of other research funders in requiring all the research they fund to be published with open access, without impacting on journal choice.⁵-⁷ In order to provide publishers the time to adapt their policies and protect their copyright interests, any variant of Creative Commons or equivalent licence could be used.

Our long-term goal

Our long-term goal is to secure authors publishing company-funded research the same terms as authors publishing research funded by other sources, so that all research can be made free to read – and reuse – from the date of publication. This would enable pharmaceutical companies to follow the lead of other research funders in maximizing the impact of the research they fund on patient health. Open Pharma is committed to working closely with publishers and pharmaceutical companies to ensure that the gold standard Creative Commons Attribution (CC BY) licence can sustainably be used.⁸

Acknowledgements

This Open Pharma position statement on open access represents the opinions of the individual members: Catherine Skobe (Pfizer), Chris Rains (Takeda), Chris Winchester (Oxford PharmaGenesis), Julie Newman (Gilead), Lise Baltzer (Novo Nordisk), Sarah Sabir (Oxford PharmaGenesis) and Valerie Philippon (Takeda), and not necessarily those of their individual companies. We thank the members, supporters and followers of Open Pharma for their input and valuable discussion.

https://doi.org/10.6084/m9.figshare.10003304
References

Endorsements

Publishers
Betasciencepress Publishing
Ecancer
F1000 Research Ltd.
Frontiers Media SA
Future Science Group
MDPI
PLOS
Wiley

Organizations
Ataxia & Me
Autoinflammatory UK
Cambridge Rare Disease Network
Centro Español de Investigación Farmacoepidemiológica (CEIFE)
Cinclus Pharma Holding AB
DSL Consulting, LLC
Galapágos NV
International Kidney Cancer Coalition
Ipsen
Kidney Research UK
M-CM Network
Observational and Pragmatic Research Institute Pte
Oxford Health Policy Forum
Oxford PharmaGenesis
Pedalling4ACure
SCN2A Australia
Scott Pharma Solutions
Solanum Medical Communications Ltd.
SUDEP Action
The Aarskog Foundation
ThinkSCIENCE, Inc.
Zimbabwe Evidence Informed Policy Network

Individuals
Mary Kunjappu, Alexion Pharmaceuticals
Kenneth Pomerantz, Alexion Pharmaceuticals
Börje Wernersson, formerly of AstraZeneca

https://doi.org/10.6084/m9.figshare.10003304
Alan Thomas, Ataxia & Me
Scott Armit, Ataxia & Me
John Wallace, Autoinflammatory UK
Gavin Giovannoni, Barts and the London School of Medicine and Dentistry
Roland J.W. Meesters, Betasciencepress Publishing
E. Andrew Balas, Biomedical Research Innovation Laboratory, Augusta University
Luis Alberto García Rodríguez, Centro Español de Investigación Farmacoepidemiológica (CEIFE)
Peter Unge, Cinclus Pharma Holding AB
Val Tate, communications consultant
Raj Kadadai, Cure SCA3
Douglas Levine, DSL Consulting
Brian S. Alper, EBSCO Information Services
Katie Foxall, ecancer
Laverne Mooney, Independent Consultant
Linda Edmonson, Innovative Strategic Communications
Tim Day, Innovative Strategic Communications
Martin Delahunty, Inspiring STEM
Anna Baikova, Ipsen
Christy Collins, M-CM Network
Grigorios Leontiadis, McMaster University
Franck Vazquez, MDPI
Rita Moreira de Silva, Medscape
Alben Sigamani, Narayana Health
Michael De Rosa, National Ataxia Foundation
Peter Llewellyn, NetworkPharma Ltd.
Pali Hungin, Newcastle University
Klaus Boberg, Novo Nordisk
Heather Piwowar, Our Research
Serena Vanzan, Oxford Brookes University
Kajsa Wilhelmsson, Oxford Health System Reform Group
Adele Buss, Oxford PharmaGenesis
Alison Hillman, Oxford PharmaGenesis
Cassy Fiford, Oxford PharmaGenesis
Emma Bolton, Oxford PharmaGenesis
Francesca Ounsworth, Oxford PharmaGenesis
Jessica Hardy, Oxford PharmaGenesis
Julie Beeso, Oxford Pharmagenesis
Mark Rolfe, Oxford PharmaGenesis
Nicolas Bertheleme, Oxford PharmaGenesis
Paul Farrow, Oxford PharmaGenesis

https://doi.org/10.6084/m9.figshare.10003304
Robert Sim, Department of Respiratory Science, University of Leicester
Iain Chalmers, Centre for Evidence-Based Medicine, University of Oxford
Edith Sim, Department of Pharmacology, University of Oxford
Chas Bountra, Nuffield Department of Clinical Medicine, University of Oxford
Stevan Harnad, University of Southampton
Álvaro Díaz, Departamento de Biociencias, Universidad de la República, Uruguay
Ronald Munatsi, Zimbabwe Evidence Informed Policy Network

Endorsements last updated on 12 March 2020